scispace - formally typeset
D

David Hendlin

Researcher at Merck & Co.

Publications -  53
Citations -  2397

David Hendlin is an academic researcher from Merck & Co.. The author has contributed to research in topics: Cephamycin & Cefoxitin. The author has an hindex of 23, co-authored 53 publications receiving 2327 citations.

Papers
More filters
Journal ArticleDOI

Phosphonomycin, a New Antibiotic Produced by Strains of Streptomyces

TL;DR: Phosphonomycin is a newly discovered antibiotic produced by streptomycetes that is effective, when administered by the oral route, to mice infected with Gram-positive or Gram-negative microorganisms.
Journal ArticleDOI

Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties.

TL;DR: A new beta-lactam antibiotic, named thienamycin, was discovered in culture broths of Streptomyces MA4297, and subsequently determined to be a hitherto unrecognized species, is designated StrePTomyces cattleya (NRRL 8057).
Journal ArticleDOI

Cephamycins, a New Family of β-Lactam Antibiotics I. Production by Actinomycetes, Including Streptomyces lactamdurans sp. n

TL;DR: A number of actinomycetes isolated from soil were found to produce one or more members of a new family of antibiotics, the cephamycins, which are structurally related to cephalosporin C.
Journal ArticleDOI

Cefoxitin, a Semisynthetic Cephamycin Antibiotic: Resistance to Beta-Lactamase Inactivation

TL;DR: The role of the constitutive and inducible enzyme in bacterial resistance to the antibiotic was investigated and enzymatic destruction of cefoxitin was found to be an important factor contributing to bacterial resistance.
Journal ArticleDOI

Cefoxitin, a Semisynthetic Cephamycin Antibiotic: Susceptibility Studies

TL;DR: Cefoxitin, 3-carbamoyloxymethyl-7-α-methoxy-7-[2-thienyl)acetamido]-3-cephem-4- carboxylic acid, is a new semisynthetic cephamycin with broad antibacterial activity.